These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 25819130)

  • 1. [Management of side effects of targeted therapies in renal cancer: iatrogenic side effects].
    Massard C; Patard JJ; Hermine O; Ravaud A
    Bull Cancer; 2011; 98(3 Suppl):S79-94. PubMed ID: 25819130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Management of side-effects of targeted therapies in renal cancer: endocrine side-effects and metabolic disorders].
    Caron P; Gravis G; Oudard S; Pignot G
    Bull Cancer; 2011; 98(3 Suppl):S47-59. PubMed ID: 25819126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Management of side effects of targeted therapies in renal cancer: cutaneous side effects].
    Robert C; Gimel P
    Bull Cancer; 2011; 98(3 Suppl):S35-46. PubMed ID: 25819125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
    Bellmunt J; Eisen T; Szczylik C; Mulders P; Porta C
    BJU Int; 2011 Apr; 107(8):1190-9. PubMed ID: 21078050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
    Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
    Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib: new drug. For some gastrointestinal stromal tumours.
    Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid dysfunctions induced by tyrosine kinase inhibitors.
    Fallahi P; Ferrari SM; Vita R; Di Domenicantonio A; Corrado A; Benvenga S; Antonelli A
    Expert Opin Drug Saf; 2014 Jun; 13(6):723-33. PubMed ID: 24821006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy for renal cell cancer: current perspectives.
    van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
    Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
    Ainsworth NL; Lee JS; Eisen T
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
    Duh MS; Dial E; Choueiri TK; Fournier AA; Antras L; Rodermund D; Neary MP; Oh WK
    Curr Med Res Opin; 2009 Aug; 25(8):2081-90. PubMed ID: 19586325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination targeted therapy in advanced renal cell carcinoma.
    Sosman J; Puzanov I
    Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
    Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
    Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment approaches in renal cell carcinoma.
    Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
    Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Alpha-interferon and mental disorders].
    Debien C; De Chouly De Lenclave MB; Foutrein P; Bailly D
    Encephale; 2001; 27(4):308-17. PubMed ID: 11686052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Managing side-effects of targeted therapies in renal cancer:surgical complications].
    Chevreau C; Méjean A; Pocard M
    Bull Cancer; 2011; 98(3 Suppl):S61-7. PubMed ID: 25819127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.
    Schmidinger M; Bellmunt J
    Cancer Treat Rev; 2010 Aug; 36(5):416-24. PubMed ID: 20163917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.